This article was originally published in The Rose Sheet
Executive SummaryMarine biotech company Aquapharm Biodiscovery Ltd and ingredient supplier Croda International sign three-year deal giving Croda exclusive license to "novel marine-derived natural products identified through the collaboration from strains from Aquapharm's proprietary microbial library for use in topical cosmetic applications in skin and hair care," according to release. Croda will provide funding for Aquapharm to conduct research, along with royalties and milestone payments on commercialization of any resulting products. "The collaboration with Aquapharm is a key part of our strategy in developing novel, sustainable solutions for the personal-care industry," says Dr. Keith Layden, president of Croda...
You may also be interested in...
In an exclusive interview with Medtech Insight, Mark Leahey, president of the Medical Device Manufacturers Association (MDMA), said the previous four Medical Device User Fee negotiations with the US FDA have set a strong foundation for the industry and the next round of negotiations should focus on tweaking past deals that are already in place. See what MDMA's president, Mark Leahey, said about it here.
US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.
Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.